British MPs say they are keen to secure a close working relationship with the European Union on drug regulation post Brexit to protect patient health and investment in the UK’s life sciences sector.
It is a common problem that concerned us. As a global pharmaceuticals and medical devices B2B online platform, Ddu invited Sherlock Chen, a senior biotech practitioner, to talk about how to develop the Indonesian market.
The 5th Myanmar International Medical Equipment, Hospital and Pharmaceutical Exhibition (PHAR-MED EXPO 2017) will be held in Myanmar's capital, Yangon, during July 5 - 7, 2017. Drugdu.com(“Ddu”), the first global pharmaceuticals and medical devices B2B online platform, will be participating in the exhibition to showcase the new method of cross-border medical trade from China.
The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
In a study conducted at York University, scientists came to the astonishing conclusion that beta blockers could protect against heart failure. This was one of the latest discoveries in a field with endless treatments managing symptoms though previously damage sustained to the heart can’t be revered.
Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.
GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.